Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens
By F. Behan, F. Iorio, G. Picco, E. Gonçalves, C. Beaver, Giorgia Migliardi, Rita Santos, Yanhua Rao, F. Sassi, M. Pinnelli and 15 more. Nature, 2019
1,126 citations recorded by the source corpus.
Functional genomics approaches can overcome limitations—such as the lack of identification of robust targets and poor clinical efficacy—that hamper cancer drug development. Here we performed genome-scale CRISPR–Cas9 screens in 324 human cancer cell lines from 30 cancer types and developed a data-driven framework to prioritize candidates for cancer therapeutics. We integrated cell fitness effects with genomic biomarkers and target tractability for drug development to systematically prioritize new targets in defined tissues and genotypes. We verified one of our most promising dependencies, the Werner syndrome ATP-dependent helicase, as a synthetic lethal target in tumours from multiple cancer types with microsatellite instability. Our analysis provides a resource of cancer dependencies, generates a framework to prioritize cancer drug targets and suggests specific new targets. The principles described in this study can inform the initial stages of drug development by contributing to a new, diverse and more effective portfolio of cancer drug targets. In a screen of 324 human cancer cell lines and utilising a systematic target prioritization framework, the Werner syndrome ATP-dependent helicase is shown to be a synthetic lethal target in tumours from multiple cancer types with microsatellite instability, providing a new target for cancer drug development.
Subfields: Molecular Biology
View Paper: https://www.semanticscholar.org/paper/3e4f0dd083653b7861ecf5f306d4fb87232ad636
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
- Mark P. Jedrychowski
- Steven P. Gygi
- Mahmoud Ghandi
- William R. Sellers
- Alexey I. Nesvizhskii
- Matthias Mann
- R. Aebersold
- J. Villén
Citations in the corpus
- Quantitative Proteomics of the Cancer Cell Line Encyclopedia (2020, background): “Multiple groups recently reported that MSI cells are sensitive to WRN loss (Behan et al., 2019; Chan et al., 2019; Lieb et al., 2019).”